Quest Diagnostics (DGX) Stock Forecast & Price Target

Compare

971 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DGX Analyst Ratings

Moderate Buy

4 Buy

7 Hold

0 Sell

Based on 11 analysts giving stock ratings to

Quest

Diagnostics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DGX Stock 12 Month Forecast

Average Price Target

$201.70

▲(13.14% Upside)

Based on 11 Wall Street analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $201.70 with a high forecast of $215.00 and a low forecast of $190.00. The average price target represents a 13.14% change from the last price of $178.28.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"147":"$147","216":"$216","164.25":"$164.3","181.5":"$181.5","198.75":"$198.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":215,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$215.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":201.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$201.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":190,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$190.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[147,164.25,181.5,198.75,216],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,181.26,183.8553846153846,186.45076923076923,189.04615384615383,191.64153846153846,194.23692307692306,196.8323076923077,199.4276923076923,202.02307692307693,204.61846153846153,207.21384615384616,209.80923076923077,212.4046153846154,{"y":215,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,181.26,182.8323076923077,184.40461538461537,185.97692307692307,187.54923076923075,189.12153846153845,190.69384615384615,192.26615384615383,193.83846153846153,195.41076923076923,196.9830769230769,198.5553846153846,200.12769230769229,{"y":201.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,181.26,181.9323076923077,182.60461538461539,183.27692307692308,183.94923076923075,184.62153846153845,185.29384615384615,185.96615384615384,186.63846153846154,187.31076923076924,187.9830769230769,188.6553846153846,189.3276923076923,{"y":190,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":150.35,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":152.41,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":158.51,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.06,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.52,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":175.74,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":172.84,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":170.09,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":177.91,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":181.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$215.00

Average Price Target$201.70

Lowest Price Target$190.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

David Westenberg

Piper Sandler

$190→$200

Hold

12.18%

Upside

Reiterated

10/27/25

Quest Diagnostics price target raised to $200 from $190 at Piper SandlerQuest Diagnostics price target raised to $200 from $190 at Piper Sandler

Cira Diagnissa

TR | OpenAI - 4o

$211→$203

Buy

13.87%

Upside

Reiterated

10/26/25

AI Generated ArticleAI Generated Article

Lisa Gill

J.P. Morgan

$190→$205

Hold

14.99%

Upside

Reiterated

10/24/25

J.P. Morgan Sticks to Their Hold Rating for Quest Diagnostics (DGX)

David S Macdonald

Truist Financial

$195→$205

Hold

14.99%

Upside

Reiterated

10/22/25

Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX)

Michael Cherny

Leerink Partners

$203→$210

Buy

17.79%

Upside

Reiterated

10/22/25

Quest Diagnostics price target raised to $210 from $203 at LeerinkQuest Diagnostics price target raised to $210 from $203 at Leerink

Luke Sergott

Barclays

$190→$195

Hold

9.38%

Upside

Reiterated

10/22/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Stryker (NYSE: SYK) and Quest Diagnostics (NYSE: DGX)

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

10/21/25

Quest Diagnostics: Strong Performance and Promising Outlook Justify Buy RatingWe look for further detail on drivers of organic growth in the quarter, as well as the team’s latest thoughts on the durability of “structural” changes to the utilization environment that is benefiting Quest. Other topics to listen for include: latest thoughts on PAMA and/or RESULTS Act, impacts from the potential expiration of ACA subsidies, the newly announced Epic partnership, M&A pipeline, and the latest on Haystack.

Tycho Peterson

Jefferies

$215

Buy

20.60%

Upside

Reiterated

10/21/25

Quest Diagnostics: Strong Financial Performance and Strategic Growth Initiatives Justify Buy RatingWe are encouraged by the organic acceleration, aided by consumer (+30-40% YTD) and are also optimistic for the Haystack MRD ramp in '26. While PAMA uncertainty remains an overhang, the core business continues to strengthen. Reiterate Buy, PT to $215. Recap. Revenues of $2.82B grew +13% y/y (+7% organic), beating consensus by +3%, while $2.60 EPS was +$0.10 above the Street ($2.50), with growth led by clinical and consumer (+30-40% YTD). By sub-segment, the physician channel grew +17% (+HSD organic) with expanded plan access and momentum from functional medicine providers, while the hospital channel grew +LSD. Volumes grew +12.5% y/y, with organic +3.9%, while revenue per requisition increased +0.8% with +3% organic growth offset by LifeLabs.

Ann Hynes

Mizuho Securities

$190→$210

Buy

17.79%

Upside

Reiterated

10/17/25

Quest Diagnostics price target raised to $210 from $190 at MizuhoQuest Diagnostics price target raised to $210 from $190 at Mizuho

Kevin Caliendo

UBS

$180→$190

Hold

6.57%

Upside

Reiterated

10/17/25

UBS Sticks to Its Hold Rating for Quest Diagnostics (DGX)

Eric Coldwell

Robert W. Baird

$194→$197

Hold

10.50%

Upside

Reiterated

10/09/25

Robert W. Baird Sticks to Their Hold Rating for Quest Diagnostics (DGX)Baird analyst Eric Coldwell raised the price target on Quest Diagnostics (NYSE: DGX) to $197.00 (from $194.00) while maintaining a Neutral rating.

Elizabeth Anderson CFA

Evercore ISI

$185→$190

Hold

6.57%

Upside

Reiterated

10/08/25

Quest Diagnostics price target raised to $190 from $185 at Evercore ISIQuest Diagnostics price target raised to $190 from $185 at Evercore ISI

Pito Chickering

Deutsche Bank

$160→$178

Hold

-0.16%

Downside

Reiterated

07/23/25

Quest Diagnostics price target raised to $178 from $160 at Deutsche BankQuest Diagnostics price target raised to $178 from $160 at Deutsche Bank

Erin Wright

Morgan Stanley

$182→$191

Buy

7.13%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating

Michael Ryskin

Bank of America Securities

$198

Buy

11.06%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

David Westenberg

Piper Sandler

$190→$200

Hold

12.18%

Upside

Reiterated

10/27/25

Quest Diagnostics price target raised to $200 from $190 at Piper SandlerQuest Diagnostics price target raised to $200 from $190 at Piper Sandler

Cira Diagnissa

TR | OpenAI - 4o

$211→$203

Buy

13.87%

Upside

Reiterated

10/26/25

AI Generated ArticleAI Generated Article

Lisa Gill

J.P. Morgan

$190→$205

Hold

14.99%

Upside

Reiterated

10/24/25

J.P. Morgan Sticks to Their Hold Rating for Quest Diagnostics (DGX)

David S Macdonald

Truist Financial

$195→$205

Hold

14.99%

Upside

Reiterated

10/22/25

Truist Financial Reaffirms Their Hold Rating on Quest Diagnostics (DGX)

Michael Cherny

Leerink Partners

$203→$210

Buy

17.79%

Upside

Reiterated

10/22/25

Quest Diagnostics price target raised to $210 from $203 at LeerinkQuest Diagnostics price target raised to $210 from $203 at Leerink

Luke Sergott

Barclays

$190→$195

Hold

9.38%

Upside

Reiterated

10/22/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Stryker (NYSE: SYK) and Quest Diagnostics (NYSE: DGX)

Andrew Brackmann

William Blair

―

Buy

―

Reiterated

10/21/25

Tycho Peterson

Jefferies

$215

Buy

20.60%

Upside

Reiterated

10/21/25

Ann Hynes

Mizuho Securities

$190→$210

Buy

17.79%

Upside

Reiterated

10/17/25

Quest Diagnostics price target raised to $210 from $190 at MizuhoQuest Diagnostics price target raised to $210 from $190 at Mizuho

Kevin Caliendo

UBS

$180→$190

Hold

6.57%

Upside

Reiterated

10/17/25

UBS Sticks to Its Hold Rating for Quest Diagnostics (DGX)

Eric Coldwell

Robert W. Baird

$194→$197

Hold

10.50%

Upside

Reiterated

10/09/25

Elizabeth Anderson CFA

Evercore ISI

$185→$190

Hold

6.57%

Upside

Reiterated

10/08/25

Quest Diagnostics price target raised to $190 from $185 at Evercore ISIQuest Diagnostics price target raised to $190 from $185 at Evercore ISI

Pito Chickering

Deutsche Bank

$160→$178

Hold

-0.16%

Downside

Reiterated

07/23/25

Quest Diagnostics price target raised to $178 from $160 at Deutsche BankQuest Diagnostics price target raised to $178 from $160 at Deutsche Bank

Erin Wright

Morgan Stanley

$182→$191

Buy

7.13%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Financial Outlook and Strategic Positioning Justify Buy Rating

Michael Ryskin

Bank of America Securities

$198

Buy

11.06%

Upside

Reiterated

07/22/25

Quest Diagnostics: Strong Performance and Growth Potential Justify Buy Rating

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Quest Diagnostics

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+1.39%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +1.39% per trade.

3 Months

xxx

Success Rate

8/9 ratings generated profit

Average Return

+5.53%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +5.53% per trade.

1 Year

Michael RyskinBank of America Securities

Success Rate

9/9 ratings generated profit

Average Return

+18.00%

reiterated a buy rating 3 months ago

Copying Michael Ryskin's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +18.00% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+21.10%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +21.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DGX Analyst Recommendation Trends

Rating

Jun 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DGX has received 4 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. DGX average Analyst price target in the past 3 months is 201.70.

Each month's total comprises the sum of three months' worth of ratings.

DGX Financial Forecast

DGX Earnings Forecast

Next quarter’s earnings estimate for DGX is $2.37 with a range of $2.28 to $2.43. The previous quarter’s EPS was $2.60. DGX beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year DGX has Preformed in-line its overall industry.

DGX Sales Forecast

Next quarter’s sales forecast for DGX is $2.75B with a range of $2.71B to $2.78B. The previous quarter’s sales results were $2.82B. DGX beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year DGX has Preformed in-line its overall industry.

DGX Stock Forecast FAQ

What is DGX’s average 12-month price target, according to analysts?

Based on analyst ratings, Quest Diagnostics’s 12-month average price target is 201.70.

What is DGX’s upside potential, based on the analysts’ average price target?

Quest Diagnostics has 13.14% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DGX a Buy, Sell or Hold?

Quest Diagnostics has a consensus rating of Moderate Buy which is based on 4 buy ratings, 7 hold ratings and 0 sell ratings.

What is Quest Diagnostics’s price target?

The average price target for Quest Diagnostics is 201.70. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $215.00 ,the lowest forecast is $190.00. The average price target represents 13.14% Increase from the current price of $178.28.

What do analysts say about Quest Diagnostics?

Quest Diagnostics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.

How can I buy shares of DGX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Quest Diagnostics (DGX) Stock Forecast & Price Target

DGX Analyst Ratings

DGX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Quest Diagnostics

DGX Analyst Recommendation Trends

DGX Financial Forecast

DGX Earnings Forecast

DGX Sales Forecast

DGX Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts